Experienced in Secondary Immunodeficiency (SID)

Dr. Jae H. Park

Otolaryngology
4100 John R St, 
Detroit, MI 
Experienced in Secondary Immunodeficiency (SID)
4100 John R St, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jae Park is an Otolaryngologist in Detroit, Michigan. Dr. Park is rated as an Experienced provider by MediFind in the treatment of Secondary Immunodeficiency (SID). His top areas of expertise are Small Lymphocytic Lymphoma (SLL), Febrile Neutropenia, Secondary Immunodeficiency (SID), Mastoidectomy, and Myringotomy.

His clinical research consists of co-authoring 288 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Secondary Immunodeficiency (SID).

Specialties
Otolaryngology
Licenses
Otolaryngology in MI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4100 John R St, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Venetoclax, Liposomal Vincristine
Study Phase: Phase 1/Phase 2
A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug, Device, Other
Study Drugs: Daunorubicin, Vincristine, Prednisone, PEG-Asparaginase, Methotrexate, 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Leucovorin, Dexamethasone
Study Phase: Phase 2
A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies
A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drug: 19(T2)28z1xx CAR-T Cells
Study Phase: Phase 1
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Dasatinib, Dexamethasone
Study Phase: Phase 1
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Biological
Study Drug: Gene-modified T cells targeted
Study Phase: Phase 1
A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL Armored Chimeric Antigen Receptor (CAR) Modified T Cells in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL Armored Chimeric Antigen Receptor (CAR) Modified T Cells in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological
Study Drug: CD19CAR-CD28-CD3zeta-EGFRt
Study Phase: Phase 1
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Biological, Drug
Study Drugs: Cytarabine, Lintuzumab, Furosemide, Spironolactone
Study Phase: Phase 1/Phase 2
A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients
A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients
Enrollment Status: Completed
Publish Date: September 11, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Enrollment Status: Withdrawn
Publish Date: June 02, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

288 Total Publications

Robust CD4 + CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Robust CD4 + CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Similar Doctors
Advanced in Secondary Immunodeficiency (SID)
Dr. Mark A. Zacharek
Otolaryngology
Advanced in Secondary Immunodeficiency (SID)
Dr. Mark A. Zacharek
Otolaryngology

Regents Of The University Of Michigan

24 Frank Lloyd Wright Dr, 
Ann Arbor, MI 
 (32.0 miles away)
734-936-8051
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Zacharek is an Otolaryngologist in Ann Arbor, Michigan. Dr. Zacharek is rated as a Distinguished provider by MediFind in the treatment of Secondary Immunodeficiency (SID). His top areas of expertise are Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Sinusitis, Empyema, and Nasal Polyps. Dr. Zacharek is currently accepting new patients.

Experienced in Secondary Immunodeficiency (SID)
Dr. Melissa A. Pynnonen
Otolaryngology
Experienced in Secondary Immunodeficiency (SID)
Dr. Melissa A. Pynnonen
Otolaryngology

Regents Of The University Of Michigan

380 Parkland Plz, 
Ann Arbor, MI 
 (38.9 miles away)
734-936-8051
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Melissa Pynnonen is an Otolaryngologist in Ann Arbor, Michigan. Dr. Pynnonen is rated as a Distinguished provider by MediFind in the treatment of Secondary Immunodeficiency (SID). Her top areas of expertise are Sinusitis, Nasal Polyps, Low Nasal Bridge, Myringotomy, and Endoscopy. Dr. Pynnonen is currently accepting new patients.

Adam J. Folbe
Experienced in Secondary Immunodeficiency (SID)
Dr. Adam J. Folbe
Otolaryngology
Experienced in Secondary Immunodeficiency (SID)
Dr. Adam J. Folbe
Otolaryngology

Corewell Health William Beaumont University Hospital Sinus & Skull Base Surgery

3555 West 13 Mile Road, Suite N120, 
Royal Oak, MI 
 (13.0 miles away)
248-551-5700
Experience:
25+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Folbe is an Otolaryngologist in Royal Oak, Michigan. Dr. Folbe has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Secondary Immunodeficiency (SID). His top areas of expertise are Pituitary Tumor, Sinus Cancer, Prolactinoma, Balloon Sinuplasty, and Septoplasty. Dr. Folbe is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Park's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile